PMID: 7031443Jan 1, 1981Paper

Stimulation of nonspecific host resistance to infection induced by muramyldipeptides

Microbiology and Immunology
K MatsumotoI Azuma

Abstract

The effect of muramyldipeptide (MDP), N-acetylmuramyl-L-alanyl-D-isoglutamine [MDP(Ala)], and its analogs on bacterial infection was studied using the experimental model of sepsis infection in mice. Injection of MDP(Ala) gave mice definitive protection against E. coli infection, but only partial protection against P. aeruginosa or K. pneumoniae infection. Several factors influencing the protective activity of MDP(Ala) on E. coli infection were studied, and it was demonstrated that the activity was induced by various routes of administration of MDP(Ala), including the oral route, and was markedly influenced by the bacterial inoculum size. It was also shown that the effective dose of MDP(Ala) was 100 micrograms per mouse for intraperitoneal, intravenous or subcutaneous injections and 1,000 microgram per mouse when administered orally. Furthermore, the optimal interval between MDP-treatment and infection was 24 hr when the treatment was carried out before infection. Clearance of bacterial cells in blood was observed after E. coli infection in mice treated with MDP(Ala). The efficacy of MDP(Ala) and two analogs, N-acetylmuramyl-L-valyl-D-isoglutamine [MDP(Val)] and N-acetylmuramyl-L-seryl-D-isoglutamine [MDP (Ser)], was evaluated f...Continue Reading

References

May 1, 1977·Proceedings of the National Academy of Sciences of the United States of America·L ChedidE Lederer
Jul 1, 1977·The Journal of Infectious Diseases·W C Buhles, M Shifrine
Jul 1, 1978·Proceedings of the National Academy of Sciences of the United States of America·M ParantL Chedid
Nov 1, 1978·The Journal of Experimental Medicine·L H BlockJ Drews
Dec 1, 1978·The Journal of Infectious Diseases·C A DinarelloS M Wolff
Jun 1, 1975·Cellular Immunology·P A CampbellC Schuffler
Jul 1, 1976·Proceedings of the National Academy of Sciences of the United States of America·L ChedidE Lederer
Feb 1, 1974·Proceedings of the National Academy of Sciences of the United States of America·R M Fauve, B Hevin
Feb 4, 1974·Biochemical and Biophysical Research Communications·A AdamE Lederer
Aug 19, 1974·Biochemical and Biophysical Research Communications·F EllouzE Lederer
May 1, 1969·The Journal of Experimental Medicine·R V BlandenG B Mackaness
Feb 1, 1980·Infection and Immunity·H Finger, C H Wirsing von König
Jan 1, 1980·International Archives of Allergy and Applied Immunology·G B West
Feb 1, 1964·The Journal of Speech and Hearing Disorders·L P GOLDSTEIN

❮ Previous
Next ❯

Citations

Apr 1, 1992·International Journal of Immunopharmacology·I Azuma
Oct 6, 2000·Journal of Controlled Release : Official Journal of the Controlled Release Society·N PuriP J Sinko
Jan 1, 1989·International Journal of Immunopharmacology·K OnozukaM Nakano
Apr 1, 1985·Journal of Comparative Pathology·K A BrogdenH D Lehmkuhl
Feb 10, 1999·Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Médicas E Biológicas·E NeumannL Q Vieira
Jan 8, 2020·Journal of Molecular Neuroscience : MN·Susanne WasmuthArnd Heiligenhaus

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.